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ABSTRACT  
Rationale: Nitric oxide (NO) is increased in the lung periphery of patients with chronic obstructive 
pulmonary disease (COPD). However, expression of the NO synthase(s) responsible for elevated 
NO has not been identified in the peripheral lung tissue of patients with COPD of varying severity. 
Objectives: 
Methods: Protein and mRNA expression of nitric oxide synthase type I (neuronal NOS [nNOS]), 
type II (inducible NOS [iNOS]), and type III (endothelial NOS [eNOS]) were quantified by 
Western blotting and reverse transcription-polymerase chain reaction, respectively, in specimens of 
surgically resected lung tissue from nonsmoker control subjects, patients with COPD of varying 
severity, and smokers without COPD, and in a lung epithelial cell line (A549). The effects of 
nitrative/oxidative stress on NOS expression and activity were also evaluated in vitro in A549 cells. 
nNOS nitration was quantified by immunoprecipitation and dimerization of nNOS was detected by 
low-temperature SDS–PAGE/Western blot in the presence of the peroxynitrite generator, 3-
morpholinosydnonimine-N-ethylcarbamide (SIN1), in vitro and in vivo. 
Measurements and Main Results: Lung tissue from patients with severe and very severe COPD had 
graded increases in nNOS (mRNA and protein) compared with nonsmokers and normal smokers. 
Hydrogen peroxide (H2O2) and SIN1 as well as the cytokine mixture (IFN-γ, IL-1β, and tumor 
necrosis factor-α) increased mRNA expression and activity of nNOS in A549 cells in a 
concentration-dependent manner compared with nontreated cells. Tyrosine nitration resulted in an 
increase in nNOS activity in vitro, but did not affect its dimerization. 
Conclusions: Patients with COPD have a significant increase in nNOS expression and activity that 
reflects the severity of the disease and may be secondary to oxidative stress. 
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AT A GLANCE COMMENTARY 
Scientific Knowledge on the Subject  
Nitric oxide is increased in the peripheral lungs of patients with chronic obstructive pulmonary 
disease (COPD); however, the source is unclear. 
What This Study Adds to the Field  
Neuronal nitric oxide synthase expression and activity are increased in patients with COPD 
according to the severity of their disease, and this may be the cause of high levels of nitrative stress 
in peripheral lung. 
Chronic obstructive pulmonary disease (COPD) is a major and increasing global health problem 
and there are no current therapies that reduce the inevitable progression of the disease. COPD is 
characterized by airflow limitation that is not fully reversible and is usually both progressive and 
associated with an abnormal inflammatory response of the lung to noxious particles or gases (1). 
Cigarette smoking is strongly linked to the ongoing inflammation in the airways and lung 
parenchyma, and the severity of airflow limitation is correlated with the degree of pulmonary 
inflammation (2, 3). 
Reactive nitrogen species, which are contained in cigarette smoke and are also produced 
endogenously, have been implicated in the pathogenesis of COPD (4). Nitric oxide (NO) is a free 
radical able to interact with superoxide anions (O2
−
) to form the strong nitrosant peroxynitrite 
(ONOO
−), which can lead to nitration (addition of −NO2) of most classes of biological molecules. 
Peroxynitrite may thus provoke inhibition of mitochondrial respiration, protein dysfunction, and 
damage to cell membranes and DNA (5). 
In asthma increased levels of exhaled NO are likely to be due to activation of the inducible form of 
NO synthase (iNOS or type II NOS) and increased iNOS expression and increased nitrotyrosine 
immunoreactivity have been reported (6). Treatment with corticosteroids in asthma results in a 
reduction of exhaled NO levels due to both reducing effects of steroids on the underlying airway 
inflammation and inhibitory effects on iNOS expression itself (6, 7). 
Exhaled NO levels in COPD are not elevated as in asthma and may be reduced by cigarette 
smoking (8, 9). Furthermore, exhaled NO levels are not reduced by steroid treatment (10). 
Partitioning of exhaled NO in COPD by measurement at various expiratory flows has suggested that 
NO may originate from the peripheral lung compartment rather than the central airways (11). 
Furthermore, nebulized aminoguanidine, a weakly selective iNOS inhibitor, markedly reduces 
(∼90%) NO produced in the central airways (JNO) in asthma (12), whereas in COPD the increased 
exhaled NO from peripheral lung (Calv) is decreased by less than 50% (13). The increase in Calv and 
exhaled ONOO
−
 levels was not completely suppressed by nebulized aminoguanidine in patients 
with COPD (13), suggesting that an isoform(s) different from iNOS may also be involved in 
peripheral NO production in patients with COPD. 
NO derived from various isoforms of NOS plays a critical and diverse physiological role and has 
been implicated in several diseases, including asthma and COPD (9). NO produced by neuronal 
NOS (nNOS, type I NOS) functions as a neurotransmitter of bronchodilator nerves, NO produced 
by endothelial NOS (eNOS, type III NOS) is a bronchial vasodilator and NO produced by iNOS is 
an effector in cytotoxicity and cytostasis and is involved in host defense (14–17). 
The paradigm of constitutive and inducible NOS isoforms has been modified from its original 
concept (18). In particular, although nNOS and eNOS are constitutively expressed—and indeed are 
sometimes collectively referred to as constitutive NOS (cNOS)—it is now apparent that their 
activity can be regulated by various factors. Conversely, iNOS may be constitutively expressed at 
certain sites. It is therefore important to determine the levels of NOS isoforms expressed in various 
organs and tissues to estimate the amount of NO produced and also to understand the in vivo actions 
of the individual NOS isoforms. 
The source of exhaled NO is unclear, although increased expression of iNOS has been reported with 
elevated exhaled NO in asthmatic airways and has been localized to the airway epithelium and 
infiltrating inflammatory cells (19). Much of the work regarding the regulation of iNOS expression 
has been performed in murine models. In these systems iNOS is readily induced and produces large 
quantities of NO. However, induction of human iNOS has proved to be more complex (20). 
An increase in iNOS expression has been reported in the bronchi of patients with COPD (21), but 
there are no studies on the expression and regulation of NOS isoforms in the peripheral lung tissue 
of patients with COPD. 
In this study we investigated the protein and mRNA expression of the three NOS isoenzymes in the 
peripheral lung tissue of patients with COPD and also studied the impact of nitrative/oxidative 
stress on NOS expression and activity in vitro in A549 cells, which are derived from alveolar 
epithelial cells. 
METHODS 
 Choose
 
 
 
Subjects  
The guidelines for grading disease severity in COPD according to the Global Initiative for Chronic 
Obstructive Lung Disease (1) were followed. Specimens of lung tissue and data on patient lung 
function were obtained from a tissue bank that was linked to an established patient registry (22). 
Specimens of peripheral lung tissue were obtained from 11 patients who were nonsmoker control 
(NSC) subjects without symptoms and had normal lung function, and from 6 smoker control (SC) 
subjects and 17 patients who were smokers: 4 with stage 1 COPD, and 11 with stage 2 COPD. 
Specimens of peripheral lung tissue were obtained from an additional 7 patients with stage 3–4 
COPD who were undergoing lung volume reduction surgery. All subjects provided written 
informed consent for the deposition of their tissues in the tissue bank from which we obtained the 
specimens and for their use in research studies of this type. 
Cell Culture  
Human lung epithelial (A549) cells were grown in culture medium (Dulbecco's modified Eagle's 
medium) to approximately 80–90% confluence and then cultured for 24 hours in additive-free 
medium before experimental treatments. A549 cells were treated with cytokine mixture (CytoMix; 
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) (IL-1β, 10 ng/ml; tumor necrosis factor-α,10 
ng/ml; IFN-γ, 100 ng/ml) or LPS (1 μg/ml), with a peroxynitrite generator (3-
morpholinosydnonimine-N-ethylcarbamide [SIN1] at 10, 100, and 500 μM) and with hydrogen 
peroxide (H2O2 at 1, 10, and 100 μM) and incubated for 8 and 24 hours to determine mRNA 
expression. 
Additional details on the method are provided in the online supplement. 
Preparation of Cell Extracts  
Peripheral lung tissue specimens (three pieces approximately 0.5 cm
3
 in size) were ground under 
liquid nitrogen, using a pestle and mortar. Hypotonic buffer (10 mM N-2-hydroxyethylpiperazine-
N′-ethane sulfonic acid–sodium hydroxide [pH 7.9], 1.5 mM magnesium chloride, 10 mM 
potassium chloride, 10 mM 2-mercaptoethanol, and one protease inhibitor cocktail tablet per 10 ml 
[Roche Diagnostics, Lewes, UK]) was added to samples to remove red blood cells and secretions 
and to loosen cell membranes, and then left for 15 minutes on ice. A549 cells were washed with ice-
cold Hanks' balance salt solution twice and scraped off. The cells were collected by spinning down 
at 12,000 rpm for 3 minutes at 4°C. 
The whole cell extraction from peripheral lung tissue or A549 cells was performed on ice. The 
radioimmunoprecipitation assay (RIPA) buffer, which contains 50 mM TRIS-HCl (pH 7.4), 2% 
Nonidet P-40, 0.5% (wt/vol) sodium deoxycholate, 150 mM NaCl, deionized water, and a protein 
inhibitor tablet (Roche Diagnostics, Mannheim, Germany), was prepared as previously reported 
(23). Samples were resuspended in RIPA buffer and left for 20 minutes on ice, and then sonicated 
with a Vibra-Cell high-density ultrasonic processor (Jencons, Leicestershire, UK) for 10 seconds at 
an amplitude of 60. Samples were then centrifuged again at 12,000 rpm for 10 minutes at 4°C. The 
supernatant was immediately transferred into fresh cold labeled microcentrifuge tubes and the 
protein concentration of the cell lysate was determined with a Bradford protein assay kit, using 
bovine serum albumin as a standard (Bio-Rad, Hemel Hempstead, UK). 
Detection of NOS Protein Expression  
Protein samples were analyzed by SDS–PAGE and Western blot analysis with the use of an 
immunoblot apparatus (XCell SureLock mini-cell and blot module kit; Invitrogen, Carlsbad, CA). 
Immunoreactive bands were detected by an enhanced chemiluminescence technique (ECL solution; 
Amersham Ltd, Amersham, UK) using specific antibodies. Variation of band density of NOS 
isoforms in different samples was corrected for the band density of β-actin (Abcam, Cambridge, 
UK). 
Additional details on the method are provided in the online supplement. 
mRNA Expression: Real-Time Quantitative Polymerase Chain Reaction  
Total RNA was extracted from approximately 1 × 10
6
 A549 cells or two specimens of lung tissue of 
0.3 cm
3
, using an RNeasy kit (Qiagen, Crawley, UK) and reverse transcription to obtain cDNA was 
performed with the use of an Omniscript RT kit (Qiagen) as previously described (24). Gene 
transcript levels of nNOS, iNOS, and eNOS were quantified by real-time polymerase chain reaction 
(PCR) using a TaqMan system (Applied Biosystems, Foster City, CA) on a Rotor-Gene 3000 
(Corbett Research, Mortlake, NSW, Australia). Variation in transcript amounts in different samples 
was corrected with glyceraldehydes-3-phosphate dehydrogenase expression. Sequences of the 
primer pairs used for the PCR are given in the online supplement. 
Immunohistochemistry  
The tissue samples had been fixed in 10% buffered formalin and embedded in paraffin, and cut. The 
immunostaining was performed with an EnVision G|2 system/AP, rabbit/mouse (DakoCytomation, 
Cambridge, UK). Comparison of immunoreactivities was conducted between three patients with 
COPD and three NSC subjects and immunostaining was evaluated by two blinded investigators. 
Negative control slides were exposed only to secondary antibodies. 
Additional details on the method are provided in the online supplement. 
Cell Viability  
Cell viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) method. None of the treatments used in this study altered cell viability when compared with 
untreated cells. 
Additional details on the method are provided in the online supplement. 
nNOS Activity Assay  
Whole cell extract of A549 cells was prepared by homogenization and incubated with an nNOS-
specific substrate (N-cyclopropyl-N
1
-hydroxyguanidine-HCl, 5 nM; Alexis Biochemicals, 
AXXORA Ltd, Nottingham, UK) for 1 hour at 30°C; released nitrite was measured to determine 
nNOS activity. 
Nitrite/Nitrate Assay  
Total nitrite released was measured with a nitrate/nitrite colorimetric assay kit (lactate 
dehydrogenase method) (AXXORA Ltd). 
Nitration of nNOS  
To test whether nNOS was a nitrated protein, two experiments were performed: in vitro and in vivo. 
An nNOS human recombinant (10 μl) (AXXORA) was incubated with SIN1 (10 and 100 μM) in 
presence of NaHCO3 (200 mM) for 1 hour at 30°C and nitrated nNOS was detected with mouse 
monoclonal anti-nitrotyrosine antibody (Upstate Biotechnology, Charlottesville, VA). Release of 
nitrite was quantified to evaluate nNOS activity. 
nNOS was immunoprecipitated by the addition of 5 μg of anti-nNOS rabbit polyclonal antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA) in whole cell extracts of A549 cells. The immune 
complex was incubated for 4 hours at 4°C. Protein A/G PLUS agarose beads (30 μl) (50% slurry; 
Santa Cruz Biotechnology) was added to the mixture to collect the nNOS immune complex or 
nitrated protein immune complex. The immune complex was then washed with RIPA solution (50 
mM TRIS-HCl [pH 7.4], 2% [vol/vol] Nonidet P-40, 0.25% [wt/vol] sodium deoxycholate, 150 
mM NaCl, and deionized water) three times and incubated with 30 μl of RIPA. Peroxynitrite was 
added at various concentrations (10, 100, and 500 μM). Western blotting was performed and bands 
were detected with anti-nNOS and anti-nitrotyrosine antibodies. 
Detection of Dimerization of NOS by Low-Temperature SDS–PAGE/Western Blot  
Recombinant nNOS was incubated with SIN1 (10 and 100 μM) and NaHCO3 (200 mM) or with 
distilled water and left for 30 minutes at 34°C. Laemmli buffer was added and each sample was 
divided into two, one of which was boiled. Low-temperature SDS—PAGE/Western blot was 
performed according to the procedures of Klatt and colleagues (25). Gels and buffers were 
equilibrated at 4°C before electrophoresis and the buffer tank was placed in an ice bath during the 
electrophoresis in a cold room to maintain the temperature of the gel below 15°C. The membrane 
was probed with anti-nNOS antibody and reprobed with anti-nitrotyrosine antibody. 
Statistical Analysis  
Data are presented as means ± the standard deviation (SD) or standard error of the mean (SEM). 
Analysis of variance was performed with the use of the nonparametric Kruskal–Wallis test. When 
the result was significant, the Mann-Whitney U test was performed for comparisons between groups 
(SPSS software; SPSS, Chicago, IL). Correlation coefficients were calculated with the use of 
Spearman's rank method. A P value of less than 0.05 was considered to indicate statistical 
significance. All reported P values are two-sided. 
RESULTS 
 Choose
 
 
 
Baseline characteristics of the patients are summarized in Table 1.  
TABLE 1  
View Larger Version  
 
SUBJECT CHARACTERISTICS. 
NOS mRNA and Protein Expression in Lung Tissues  
There was a significant increase in iNOS mRNA expression (P < 0.05) in samples from patients 
with stage 2 disease (65.2 ± 23) and the values were also higher in peripheral lung tissue from 
patients with more severe COPD (stage 3, 79.1 ± 13.2; stage 4, 78.9 ± 22.3) compared with samples 
from NSC subjects (12.5 ± 6.6). There were no significant differences in the levels of iNOS mRNA 
between samples from SC subjects (22.2 ± 8.9), patients with stage 1 disease (17.2 ± 12.6), or from 
NSC subjects (Figure 1A).  
Figure 1 
 
Figure 1. Messenger RNA expression of nitric oxide synthase (NOS) isoenzymes in human 
peripheral lung tissue from nonsmoker control (NSC) subjects, smoker control (SC) subjects, and 
patients with chronic obstructive pulmonary disease (COPD) at Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) stage 1, 2, 3, or 4. The results are plotted as means ± SEM; *P < 
0.05 versus nonsmokers. (A) iNOS mRNA expression; (B) nNOS mRNA expression; (C) eNOS 
mRNA expression. eNOS = endothelial nitric oxide synthase; iNOS = inducible nitric oxide 
synthase; nNOS = neuronal nitric oxide synthase. 
Messenger RNA expression of nitric oxide synthase (NOS) isoenzymes in human peripheral lung 
tissue from nonsmoker control (NSC) subjects, smoker control (SC) subjects, and patients with 
chronic obstructive pulmonary disease (COPD) at Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) stage 1, 2, 3, or 4. [More] 
Messenger RNA expression of nitric oxide synthase (NOS) isoenzymes in human peripheral lung 
tissue from nonsmoker control (NSC) subjects, smoker control (SC) subjects, and patients with 
chronic obstructive pulmonary disease (COPD) at Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) stage 1, 2, 3, or 4. The results are plotted as means ± SEM; *P < 0.05 versus 
nonsmokers. (A) iNOS mRNA expression; (B) nNOS mRNA expression; (C) eNOS mRNA 
expression. eNOS = endothelial nitric oxide synthase; iNOS = inducible nitric oxide synthase; 
nNOS = neuronal nitric oxide synthase. [Minimize] 
iNOS protein expression levels reached significance (P < 0.05) in samples from patients with stage 
1 disease (1.2 ± 0.1, iNOS/β-actin) and patients with stage 2 disease (1.8 ± 0.2) as compared with 
those from NSC subjects (0.6 ± 0.2); iNOS protein expression levels did not show a significant 
difference at stage 3 (1.9 ± 0.5) and stage 4 (1.8 ± 0.3) disease compared with levels from patients 
with stage 1 and 2 disease, although the values were increased (P < 0.05) compared with those of 
NSC and SC subjects (0.9 ± 0.2) (Figure 2A).  
Figure 2 
 
Figure 2. Protein expression of nitric oxide synthase (NOS) isoenzymes in peripheral lung tissue 
from nonsmoker control (NSC) subjects, smoker control (SC) subjects, and patients with chronic 
obstructive pulmonary disease (COPD) at Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) stage 1, 2, 3, or 4. The samples were analyzed in a blinded manner and the samples from 
each subject group of each disease stage were randomly distributed on the blots. Therefore the 
representative image of each disease stage has been selected and provided. The statistical analysis 
of density was determined from the original gels and the data were not corrected. Densitometric 
analyses are normalized to β-actin and expressed as means ± SEM. *P < 0.05 versus nonsmokers; 
**P < 0.0001 versus nonsmokers. (A) iNOS protein expression; (B) nNOS protein expression; (C) 
eNOS protein expression; (D) correlation between nNOS protein expression levels and FEV1 (% 
predicted) in all study groups; (E) correlation between nNOS protein expression levels and 
FEV1/FVC (% predicted) in all study groups; (F) correlation between nNOS protein expression 
levels and FEV1 (% predicted) only in patients with COPD; (G) correlation between nNOS protein 
expression levels and FEV1/FVC (% predicted) only in patients with COPD. eNOS = endothelial 
nitric oxide synthase; iNOS = inducible nitric oxide synthase; nNOS = neuronal nitric oxide 
synthase. 
Protein expression of nitric oxide synthase (NOS) isoenzymes in peripheral lung tissue from 
nonsmoker control (NSC) subjects, smoker control (SC) subjects, and patients with chronic 
obstructive pulmonary disease (COPD) at Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) stage 1, 2, 3, or 4. [More] 
Protein expression of nitric oxide synthase (NOS) isoenzymes in peripheral lung tissue from 
nonsmoker control (NSC) subjects, smoker control (SC) subjects, and patients with chronic 
obstructive pulmonary disease (COPD) at Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) stage 1, 2, 3, or 4. The samples were analyzed in a blinded manner and the samples from 
each subject group of each disease stage were randomly distributed on the blots. Therefore the 
representative image of each disease stage has been selected and provided. The statistical analysis 
of density was determined from the original gels and the data were not corrected. Densitometric 
analyses are normalized to β-actin and expressed as means ± SEM. *P < 0.05 versus nonsmokers; 
**P < 0.0001 versus nonsmokers. (A) iNOS protein expression; (B) nNOS protein expression; (C) 
eNOS protein expression; (D) correlation between nNOS protein expression levels and FEV1 (% 
predicted) in all study groups; (E) correlation between nNOS protein expression levels and 
FEV1/FVC (% predicted) in all study groups; (F) correlation between nNOS protein expression 
levels and FEV1 (% predicted) only in patients with COPD; (G) correlation between nNOS protein 
expression levels and FEV1/FVC (% predicted) only in patients with COPD. eNOS = endothelial 
nitric oxide synthase; iNOS = inducible nitric oxide synthase; nNOS = neuronal nitric oxide 
synthase. [Minimize] 
Increased nNOS mRNA expression reached significance (P < 0.05) in peripheral lung tissue from 
patients with stage 1 disease (416.4 ± 76.2) and stage 2 disease (477.1 ± 43.3) as compared with 
those from NSC subjects (211.6 ± 54) and from SC subjects (261.3 ± 45.2); nNOS mRNA levels 
were also higher from patients with stage 3 disease (677.2 ± 19) and stage 4 disease (642.3 ± 29), 
although the levels were not significantly different between the two groups (Figure 1B). 
A similar trend with nNOS mRNA was also noted in the protein expression levels for nNOS: there 
were no significant differences in the levels of nNOS between samples from SC subjects (0.85 ± 
0.2), patients with stage 1 disease (0.75 ± 0.24), and samples from NSC subjects (0.78 ± 0.21); the 
differences became significant between samples from NSC subjects and those from patients with 
stage 2 disease (1.3 ± 0.18; P < 0.05), stage 3 disease (4.2 ± 1.6; P < 0.05), and stage 4 disease (3.9 
± 0.7; P < 0.0001) (Figure 2B). Lung samples from SC subjects had lower nNOS levels compared 
with those from patients with stage 3 disease (P < 0.0001) and stage 4 disease (P < 0.0001) and 
samples from patients with stage 2 disease had lower levels (P < 0.0001) compared with samples 
from patients with stage 3 and 4 disease. 
No differences were found in eNOS mRNA levels between NSC subjects (101 ± 48) and SC 
subjects (148.8 ± 76.6) and patients with COPD at stage 1 (157.3 ± 48.6) and stage 2 (135.5 ± 35), 
but a significant reduction was found at stage 3–4 (17.6 ± 9.5; P < 0.05) (Figure 1C). 
A similar trend with eNOS mRNA was noted in the eNOS protein expression levels: there were no 
significant differences in the levels of eNOS between samples from SC subjects (0.5 ± 0.07), 
patients with stage 1 disease (0.5 ± 0.04), stage 2 disease (0.4 ± 0.04), stage 3 disease (0.37 ± 0.09), 
and samples from NSC subjects (0.4 ± 0.07); the differences became significant with samples from 
patients with stage 4 disease (0.13 ± 0.02; P < 0.05) (Figure 2C). 
nNOS protein expression was correlated with FEV1 (% predicted) (r = −0.7, P < 0.0001) and 
FEV1/FVC (r = −0.65, P < 0.0001) in a Spearman correlation analysis (Figures 2D and 2E, 
respectively) in all studied groups. Interestingly, these correlations were preserved when healthy 
subjects were excluded from the analysis (Figures 2F and 2G, respectively). No correlations were 
found between iNOS or eNOS and lung function parameters. 
Immunohistochemistry showed that the alveolar epithelium in peripheral lung tissue from patients 
with COPD was strongly positive for nNOS (Figure 3C), whereas specimens of healthy control 
subjects exhibited only a little immunoreactivity (Figure 3B).  
Figure 3 
 Figure 3. Immunohistochemical localization of neuronal nitric oxide (NO) synthase expression in 
peripheral lung images of lung tissue. Representative photomicrographs show the alveolar 
epithelium from (A) a negative control subject (original magnification, ×100), (B) a healthy control 
subject (original magnification, ×200), and (C) a patient with chronic obstructive pulmonary disease 
(COPD) (original magnification, ×200) immunostained for identification of neuronal nitric oxide 
synthase (red color). Inset: Alveolar epithelium at a higher magnification. Arrows indicate 
representative positively stained cells. 
Immunohistochemical localization of neuronal nitric oxide (NO) synthase expression in peripheral 
lung images of lung tissue. [More] 
Immunohistochemical localization of neuronal nitric oxide (NO) synthase expression in peripheral 
lung images of lung tissue. Representative photomicrographs show the alveolar epithelium from (A) 
a negative control subject (original magnification, ×100), (B) a healthy control subject (original 
magnification, ×200), and (C) a patient with chronic obstructive pulmonary disease (COPD) 
(original magnification, ×200) immunostained for identification of neuronal nitric oxide synthase 
(red color). Inset: Alveolar epithelium at a higher magnification. Arrows indicate representative 
positively stained cells. [Minimize] 
Effect of Reactive Oxygen Species/Reactive Nitrogen Species on nNOS Expression and Activity in 
A549 Cells  
The effect of H2O2 and SIN1 on nNOS expression was evaluated in A549 cells in vitro. H2O2 and 
SIN1 concentration-dependently increased nNOS mRNA expression (H2O2: 1 μM, 0.018 ± 0.003; 
10 μM, 0.030 ± 0.0015; 100 μM, 0.07 ± 0.01, SIN1: 10 μM, 0.021 ± 0.002; 100 μM, 0.028 ± 0.005; 
500 μM, 0.051 ± 0.006) and similar results were seen with cytomix (0.067 ± 0.01), compared with 
nontreated cells (0.003 ± 0.004) (Figure 4A).  
Figure 4 
 
Figure 4. Effect of reactive oxygen and nitrogen species on nitric oxide synthase (NOS) isoform 
expression and activity in A549 cells. A549 cells were cultured for 8 hours in the absence or 
presence of hydrogen peroxide (H2O2, at 1, 10, and 100 μM), 3-morpholinosydnonimine-N-
ethylcarbamide (SIN1, at 10, 100, and 500 μM), and cytomix (Cyt: IFN-γ [100 μg/ml], tumor 
necrosis factor-α [10 μg/ml], IL-1β [10 μg/ml], and LPS [1 μg/ml]). (A) Neuronal nitric oxide 
synthase (nNOS) mRNA expression normalized to glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH); values are plotted as means ± SD. *P < 0.05; **P < 0.001 versus nonstimulated cells. 
Data are representative of n = 3 experiments. (B) nNOS protein expression levels normalized to β-
actin; values are plotted as means ± SD. *P < 0.05; **P < 0.001 versus nonstimulated cells. Data 
are representative of n = 3 experiments. The samples were analyzed in a blinded manner and the 
samples from each treatment were randomly distributed on the blots. Therefore the representative 
image of each treatment has been selected and provided. (C) nNOS activity measured with an 
nNOS-specific substrate, with measurement of nitrite formation. Values are shown as means ± SD. 
*P < 0.05; **P < 0.001 versus nonstimulated cells. Data are representative of n = 3 experiments. 
Effect of reactive oxygen and nitrogen species on nitric oxide synthase (NOS) isoform expression 
and activity in A549 cells. [More] 
Effect of reactive oxygen and nitrogen species on nitric oxide synthase (NOS) isoform expression 
and activity in A549 cells. A549 cells were cultured for 8 hours in the absence or presence of 
hydrogen peroxide (H2O2, at 1, 10, and 100 μM), 3-morpholinosydnonimine-N-ethylcarbamide 
(SIN1, at 10, 100, and 500 μM), and cytomix (Cyt: IFN-γ [100 μg/ml], tumor necrosis factor-α [10 
μg/ml], IL-1β [10 μg/ml], and LPS [1 μg/ml]). (A) Neuronal nitric oxide synthase (nNOS) mRNA 
expression normalized to glyceraldehydes-3-phosphate dehydrogenase (GAPDH); values are 
plotted as means ± SD. *P < 0.05; **P < 0.001 versus nonstimulated cells. Data are representative 
of n = 3 experiments. (B) nNOS protein expression levels normalized to β-actin; values are plotted 
as means ± SD. *P < 0.05; **P < 0.001 versus nonstimulated cells. Data are representative of n = 3 
experiments. The samples were analyzed in a blinded manner and the samples from each treatment 
were randomly distributed on the blots. Therefore the representative image of each treatment has 
been selected and provided. (C) nNOS activity measured with an nNOS-specific substrate, with 
measurement of nitrite formation. Values are shown as means ± SD. *P < 0.05; **P < 0.001 versus 
nonstimulated cells. Data are representative of n = 3 experiments. [Minimize] 
As shown in Figure 4B, protein expression of nNOS was also increased by stimulation with H2O2 
(0.28 ± 0.02), SIN1 (0.44 ± 0.03), and cytomix (0.22 ± 0.04) when normalized to β-actin protein as 
endogenous standard. 
nNOS activity in cell extracts, which was measured with the nNOS-selective substrate N-
cyclopropyl-N
1
-hydroxyguanidine-HCl, increased after stimulation with SIN1 (10 μM, 0.033 ± 
0.0028; 100 μM, 0.0395 ± 0.005) for 24 hours compared with nonstimulated cells (0.016 ± 0.003). 
H2O2 also induced nNOS activity in a concentration-dependent manner (10 μM, 0.029 ± 0.006; 100 
μM, 0.036 ± 0.006). Cytomix also increased nNOS activity (0.027 ± 0.003) (Figure 4C). However, 
SIN1 increased nNOS activity to a greater extent than mRNA expression when compared with the 
effects of cytomix. 
Nitration of nNOS  
As shown in Figure 5A, 3-nitrotyrosine was increased in recombinant nNOS after SIN1 treatment, 
suggesting that nNOS is a nitrated protein (SIN1: 10 μM, 15% increased; 100 μM, 22.3% 
increased). Immunoprecipitated nNOS in cells treated with peroxynitrite was clearly nitrated by 
peroxynitrite in a concentration-dependent manner (10 nM, 10.5% increase in nitrotyrosine 
positivity; 100 nM, 36.8% increase; 500 nM, 73.7% increase) (Figure 5B). This increase in nNOS 
nitration paralleled an increase in nNOS activity in the in vitro experiment with recombinant nNOS 
(Figure 5C) and in A549 cells (NS: 0.03 ± 0.01; SIN1, 100 μM: 0.096 ± 0.026) (Figure 5D).  
Figure 5 
 
Figure 5. Nitration and dimerization of neuronal nitric oxide synthase (nNOS). (A) Human 
recombinant nNOS was incubated without or with 3-morpholinosydnonimine-N-ethylcarbamide 
(SIN1; 10 and 100 μM) in the presence of NaHCO3 (200 mM) for 1 hour at 30°C and nitrated 
nNOS was detected with an anti-nitrotyrosine antibody. The blot is representative of n = 3 
experiments. (B) nNOS was immunoprecipitated from A549 cells by the addition anti-nNOS 
antibody and the immunocomplex was incubated without or with peroxynitrite (PN) at various 
concentrations (nanomolar) and bands were detected with nitrotyrosine and an nNOS antibody. 
Columns graphically represent the densitometric values and are representative of n = 3 experiments. 
Data are expressed as means ± SEM. (C) Human recombinant nNOS was incubated with or without 
SIN1 in the presence of NaHCO3 (200 mM) for 1 hour at 30°C and nNOS activity was measured 
with the substrate N-cyclopropyl-N
1
-hydroxyguanidine-HCl. Data are representative of three 
experiments and the columns and error bars represent means ± SEM. (D) nNOS was 
immunoprecipitated from A549 cells by the addition of anti-nNOS rabbit polyclonal antibody and 
the resulting immunocomplex was subjected to nitration by incubation with NaHCO3 (200 mM) and 
SIN1 (500 μM) or exposed to NaHCO3 (200 mM) alone as a control. nNOS substrate was added 
and the release of nitrite was determined to quantify nNOS activity. Columns and error bars 
represent means ± SEM and are representative of three experiments. (E) Endothelial nitric oxide 
synthase (eNOS) expression in denatured/nondenatured samples in the presence and absence of 
SIN1. Bands corresponding to higher molecular weight represent eNOS dimers and the bands of 
lower molecular weight to eNOS monomers. (F) nNOS expression in denatured/nondenatured 
samples in the presence and absence of SIN1. Bands corresponding to higher molecular weight 
represent nNOS dimers and the bands of lower molecular weight to nNOS monomers. 
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Nitration and dimerization of neuronal nitric oxide synthase (nNOS). (A) Human recombinant 
nNOS was incubated without or with 3-morpholinosydnonimine-N-ethylcarbamide (SIN1; 10 and 
100 μM) in the presence of NaHCO3 (200 mM) for 1 hour at 30°C and nitrated nNOS was detected 
with an anti-nitrotyrosine antibody. The blot is representative of n = 3 experiments. (B) nNOS was 
immunoprecipitated from A549 cells by the addition anti-nNOS antibody and the immunocomplex 
was incubated without or with peroxynitrite (PN) at various concentrations (nanomolar) and bands 
were detected with nitrotyrosine and an nNOS antibody. Columns graphically represent the 
densitometric values and are representative of n = 3 experiments. Data are expressed as means ± 
SEM. (C) Human recombinant nNOS was incubated with or without SIN1 in the presence of 
NaHCO3 (200 mM) for 1 hour at 30°C and nNOS activity was measured with the substrate N-
cyclopropyl-N1-hydroxyguanidine-HCl. Data are representative of three experiments and the 
columns and error bars represent means ± SEM. (D) nNOS was immunoprecipitated from A549 
cells by the addition of anti-nNOS rabbit polyclonal antibody and the resulting immunocomplex 
was subjected to nitration by incubation with NaHCO3 (200 mM) and SIN1 (500 μM) or exposed to 
NaHCO3 (200 mM) alone as a control. nNOS substrate was added and the release of nitrite was 
determined to quantify nNOS activity. Columns and error bars represent means ± SEM and are 
representative of three experiments. (E) Endothelial nitric oxide synthase (eNOS) expression in 
denatured/nondenatured samples in the presence and absence of SIN1. Bands corresponding to 
higher molecular weight represent eNOS dimers and the bands of lower molecular weight to eNOS 
monomers. (F) nNOS expression in denatured/nondenatured samples in the presence and absence of 
SIN1. Bands corresponding to higher molecular weight represent nNOS dimers and the bands of 
lower molecular weight to nNOS monomers. [Minimize] 
Dimerization of NOS  
Dimerized eNOS was found under nondenaturing conditions and this dimerization was abolished 
under denaturing conditions (Figure 5E). The dimer-to-monomer ratio as determined by 
densitometry was 4.6 at baseline and was reduced by SIN1 treatment to 1.4, indicating that SIN1 
reduces dimerization of eNOS. By contrast, although nNOS was also dimerized at baseline (Figure 
5F), SIN1 did not affect nNOS dimerization (dimer-to-monomer ratio, 0.98 and 1.07 in the absence 
and in the presence of SIN1, respectively). 
DISCUSSION 
 Choose
 
 
 
We have demonstrated the expression of all three isoforms of NOS in human peripheral lung, both 
at the mRNA and protein levels. In the peripheral lung tissue of patients with COPD, iNOS mRNA 
expression was increased at earlier stages of the disease (GOLD stages 1 and 2) but decreased in the 
patients with the most severe disease (GOLD stages 3 and 4). Protein expression also increased at 
earlier stages of COPD, in agreement with mRNA expression, but was not reduced at later stages of 
the disease. 
Also, proinflammatory cytokine-induced iNOS expression was decreased by oxidative stress, such 
as hydrogen peroxide (H2O2), cigarette smoke–conditioned medium (CSM), and the peroxynitrite 
generator SIN1 (data not shown), consistent with findings in severe COPD, in which there is a high 
level of oxidative stress and peroxynitrite formation (13, 26, 27). 
It is important to note that some of the patients were treated with inhaled corticosteroids, but there 
did not appear to be any obvious difference in iNOS between patients who were treated with 
corticosteroids. In any case, it is unlikely that steroids would inhibit iNOS in patients with COPD, 
as there is no effect of high-dose inhaled steroid on exhaled NO in patients with COPD (11). 
Furthermore, it is likely that the inflammation that induces iNOS is steroid resistant in patients with 
COPD. 
Expression of eNOS mRNA and protein, which occurs mainly in epithelial and endothelial cells, 
did not change in mild to moderate COPD, but was reduced in the more severe stages of COPD. 
This might be a reflection of the destruction of alveoli, which leads to a loss of epithelial and 
endothelial cells in these patients as a result of emphysema. Despite the eNOS/iNOS reduction in 
severe COPD, we have previously shown an increase in exhaled NO derived from peripheral lung 
(Calv) in COPD in GOLD stages 2 and 4 (11). In the present study, nNOS protein and mRNA 
expression increased with severity of disease and there was a significant increase at stages 2, 3, and 
4, with a positive correlation between nNOS protein expression and disease severity as measured by 
the percentage of predicted FEV1 and with the degree of airway obstruction as measured by the 
FEV1/FVC ratio. Our results suggest that the main source of Calv is likely to be nNOS in the severe 
stages of the disease, whereas iNOS is involved in NO elevation mainly in the less severe stages of 
COPD. Barreiro and colleagues have also reported an elevation of nNOS in skeletal muscle of 
patients with COPD, suggesting that there may be common mechanisms for its elevation in 
peripheral lung and skeletal muscle (28). In the present study, the alveolar epithelium showed 
nNOS immunoreactivity in COPD. Furthermore, an alveolar type II cell line, A549, clearly 
expressed nNOS as well as iNOS isoforms. 
The present study showed that nNOS expression was induced by nitrative stress and oxidative stress 
as well as inflammatory cytokine stimulation. Jang and colleagues have previously demonstrated 
nNOS expression in the lung after ozone exposure, but not after allergen exposure, and it is 
interesting that this was accompanied by a reduction in iNOS expression, consistent with our 
findings in patients with COPD (29). Higher levels of oxidative and nitrative stress are seen in 
patients with COPD (21) and we now report an increase in nNOS expression. Li and colleagues 
(30) showed that acetylated NF-κB preferably bound to the promoter of nNOS although 
nonmodified NF-κB is a well-known iNOS inducer. Nitrative stress and oxidative stress induce a 
defect of SIRT1 (sirtuin 1), which deacetylates acetylated NF-κB (31). Thus, oxidative 
stress/nitrative stress induces acetylated NF-κB due to SIRT1 reduction. 
Increased oxidative/nitrative stress seen in the periphery of the lung of patients with COPD may 
account for the increased expression of nNOS in alveolar epithelial cells, thus contributing to the 
increase in Calv. However, more importantly, we found that nNOS activity is higher in nNOS 
mRNA expression under nitrative stress. We found that SIN1 increased nNOS activity to a greater 
extent than inflammatory cytokines despite a more potent induction of nNOS mRNA by cytomix 
than SIN1 at 100 nM. This suggests that the increase in nNOS activity is due at least in part to some 
posttranscriptional modification and that the increase in nNOS may involve not only increased gene 
expression but also increased enzyme activity. 
The activity of nNOS is dependent on several cofactors, such as calmodulin and flavins. The 
binding of the calcium–calmodulin complex in the presence of oxygen and nicotinamide adenine 
dinucleotide phosphate (NADPH) activates the enzyme to convert l-arginine to NO. Recognition 
sites for NADPH, flavin mononucleotide (FMN), and flavin adenine dinucleotide (FAD) have been 
identified within the nNOS molecule (32). Biochemical studies have demonstrated that FAD and 
FMN bind in stoichiometric amounts to nNOS. The reaction mechanism is believed to involve 
reduction of FAD by NADPH, which then reduces FMN, which in turn transfers electrons to the 
ferric heme moiety, allowing an interaction with molecular oxygen. It has been shown that 
dimerization is required for the catalytic activity of all three NOS isoforms (33, 34). The process of 
dimerization appears to be dependent on the presence of the cofactors heme and tetrahydrobiopterin 
(BH4), as well as the enzyme substrate l-arginine. These factors are thought to associate with the N-
terminal, heme-binding region of the protein. However, it is unclear whether sequences within the 
reductase domain are also important for dimerization. Ravi and colleagues (35) showed that in the 
eNOS enzyme intrasubunit cysteine and the tetrathiolate cysteine residues are important for dimer 
maintenance and enzyme activity; the loss of zinc due to tetrathiolate cluster oxidation by NO at the 
dimeric interface may lead to altered pterin binding, making the enzyme unstable. This effect in 
combination with intrasubunit nitrosylation may lead to dimer collapse. In our study nNOS was 
found to be nitrated and nitration of nNOS preserves its activity, in contrast to eNOS activity, which 
has been shown to be abolished by nitration (35). In fact, nitration of eNOS inhibited its 
dimerization whereas nitration of nNOS had no effect on dimerization. iNOS activity was also 
found to be reduced by oxidative stress. Thus, as nNOS activity was not affected by nitrative stress, 
in contrast to eNOS and iNOS, this suggests that nNOS is predominantly involved in the NO 
production seen in peripheral lung tissue of patients with severe COPD. 
In addition, we speculate that nitration itself might increase its activity. Although many of the 
proteins such as IL-8, histone deacetylase, and manganese-superoxide dismutase were reported to 
reduce their activity after nitration (36, 37), matrix metalloproteinase-3 activity is reported to be 
enhanced by nitration (38). The tyrosine residues nitrated in nNOS have not yet been identified, 
however. We have not yet explored the molecular mechanisms and signal transduction pathways 
whereby oxidative and nitrative stress may affect nNOS activity; this is beyond the scope of this 
study but an area for future research. 
An increase in lung nNOS expression in patients with severe COPD in combination with increased 
superoxide anion formation would result in the local formation of peroxynitrite and nitration of 
tyrosine residues on several target proteins. 
Although it is difficult to assess the functional relevance of our findings, two hypotheses are 
proposed: 
 An increase in nNOS expression may be a compensatory mechanism, as in some experimental 
systems nNOS has been found to have a protective and antiinflammatory effect. 
 An increase in lung nNOS expression in patients with severe COPD is a pathological process 
whose combination with excessive superoxide anion leads to the formation of the highly 
reactive oxidant peroxynitrite and the development of nitrosative stress. 
This speculation is supported by the elevated NO levels in peripheral lungs, elevated peroxynitrite 
levels in exhaled breath condensate, and elevated nitrotyrosine levels in patients with COPD (13, 
21, 39). This, along with the absence of abundant iNOS expression in more severe COPD, suggests 
that an increase in nNOS expression may contribute significantly to NO and peroxynitrite 
production in peripheral lungs. 
De Sanctis and colleagues showed that nNOS contributes significantly to the NO in exhaled air and 
that NO derived from nNOS contributes to baseline airway responsiveness and increased airway 
responsiveness after allergen challenge in mice (40). Jang and colleagues demonstrated that eNOS 
and nNOS isoforms induce airway responsiveness in mice after ozone exposure, whereas iNOS is 
decreased, suggesting that eNOS and nNOS contribute to the formation of NO metabolites in mice 
after ozone exposure (29, 41). Grasemann and colleagues investigated the existence of a genetic 
association between a polymorphism in the nNOS gene and the diagnosis of asthma, concluding 
that nNOS may be a candidate gene for asthma (42). In human lung nNOS is expressed 
predominantly in capillary endothelial cells of alveolar septa and may play a role as an 
endothelium-derived regulator of capillary permeability, a modulator of cholinergic neuronal 
transmission, or an inhibitor of platelet aggregation (43). 
Our data support the hypothesis that cNOS is involved in the regulation of nitrative stress and on 
the basis of this hypothesis, although the high levels of iNOS-derived NO should be considered as a 
marker of inflammatory activity in the disease, an opposing effect could be played by the levels of 
cNOS-derived NO (i.e., having a protective role). The existence of a microenvironment-dependent 
and biochemical model of NO regulation is based on different levels of NOS expression and 
activation and different responses to NO. This model should be considered when predicting the 
progression and/or natural history of the disease in individual patients and when identifying new 
therapeutic strategies aimed at selectively potentiating the cNOS pathway and reducing the 
amplified inflammatory “iNOS arginase cascade.” 
Unfortunately, we used archived lung from a tissue bank and were not able to measure Calv in this 
study, and thus cannot correlate this with nNOS expression. 
Further light may be shed on this question when highly selective iNOS and nNOS inhibitors 
become available for clinical studies. 
We do believe that nNOS might contribute to COPD pathogenesis, although this is speculation that 
cannot be explored further until clinical trials with selective nNOS inhibitors are conducted. On the 
basis of data from animal studies using nNOS knockout mice (44), NO derived from nNOS likely 
contributes to airway disease pathogenesis. We should emphasize that our study does not exclude 
the possibility that an additional mechanism other than peroxynitrite might be involved in nNOS 
activation. The exact mechanisms responsible for the elevation of nNOS expression in the 
peripheral lung tissue of patients with severe COPD are unknown. A possible mechanism may 
involve pathological conditions in which proinflammatory cytokines and mediators are elevated, 
where an increase in nNOS expression may be expected. 
Thus, increased production of NO in the peripheral lung tissue of patients with COPD depends 
mainly on nNOS, and may account for the increased production of peroxynitrite, thus amplifying 
nitrative stress that further increases the expression of NOS isoforms responsible for the increased 
production of NO. This vicious cycle of nitrative stress with a continuous balance/imbalance 
between nNOS and iNOS might be involved in the inflammation and progression of the 
pathogenesis of COPD. 
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